12:00 AM
 | 
Sep 10, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Spiriva HandiHaler tiotropium: Additional Phase IIIb data

A retrospective analysis of a subgroup of 2,012 low-risk patients with moderate to severe COPD in the double-blind, international Phase IIIb UPLIFT trial showed that Spiriva HandiHaler tiotropium significantly reduced mean annual rate of exacerbations over the 4-year trial by 28% vs. placebo (0.43 vs. 0.61; p<0.0001). Compared to placebo, Spiriva significantly reduced the time to first exacerbation by 24% and St. George's Respiratory Questionnaire (SGRQ) total score at 4...

Read the full 328 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >